X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to accelerate Endevica’s development of advanced GPCR-targeting therapeutics on receptor sets both novel and complimentary to its lead compound to creat first-in-class therapeutics for cachexia caused by cancer and other chronic conditions.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Recipient: Orbit Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2023
Details:
TCMCB07 is melanocortin‐3/4 antagonist peptide candidate in designed to be first-in-class peptide drug with ability to cross blood-brain barrier and act on previously inaccessible target receptors to modulate body’s behavioral and metabolic response to chronic illness.
Lead Product(s): TCMCB07
Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
TCMCB07 is melanocortin‐4 antagonist peptide candidate in reatment of cachexia, is designed to be first-in-class peptide drug with ability to cross BBB and act on previously inaccessible target receptors to modulate body’s behavioral and metabolic response to chronic illness.
Lead Product(s): TCMCB07
Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes.
Lead Product(s): TCMCB07
Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Endevica’s lead compound, TCMCB07, describes unique mechanisms and properties of drug, specifically in treatment of cachexia, and potential for producing a platform for drug-like peptides based on the evidence.
Lead Product(s): TCMCB07
Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
TCMCB07 can preserve lean mass as well as attenuate muscle wasting and body weight loss during cancer cachexia. The authors concluded that TCMCB07 is a promising drug candidate with universal effects on treating cancer cachexia.
Lead Product(s): TCMCB07
Therapeutic Area: Oncology Product Name: TCMCB07
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
